These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32292577)

  • 61. Correction: Targeting a ribonucleoprotein complex containing the caprin-1 protein and the c-Myc mRNA suppresses tumor growth in mice: an identification of a novel oncotarget.
    Qiu YQ; Yang CW; Lee YZ; Yang RB; Lee CH; Hsu HY; Chang CC; Lee SJ
    Oncotarget; 2019 Aug; 10(47):4919. PubMed ID: 31448057
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations.
    Samant TS; Dhuria S; Lu Y; Laisney M; Yang S; Grandeury A; Mueller-Zsigmondy M; Umehara K; Huth F; Miller M; Germa C; Elmeliegy M
    Clin Pharmacol Ther; 2018 Aug; 104(2):374-383. PubMed ID: 29134635
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Correction: The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia.
    Li X; Yin X; Wang H; Huang J; Yu M; Ma Z; Li C; Zhou Y; Yan X; Huang S; Jin J
    Oncotarget; 2019 Nov; 10(61):6641-6642. PubMed ID: 31762943
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Correction: A novel highly potent trivalent TGF-β receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands.
    Qin T; Barron L; Xia L; Huang H; Villarreal MM; Zwaagstra J; Collins C; Yang J; Zwieb C; Kodali R; Hinck CS; Kim SK; Reddick RL; Shu C; O'Connor-McCourt MD; Hinck AP; Sun LZ
    Oncotarget; 2017 Aug; 8(34):57905. PubMed ID: 28915722
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Correction: Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer.
    Guido BC; Brandão DC; Barbosa ALA; Vianna MJX; Faro L; Ramos LM; Nihi F; de Castro MB; Neto BAD; Corrêa JR; Báo SN
    Oncotarget; 2022; 13():1068. PubMed ID: 36187557
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Inhibitors of cyclin-dependent kinases (CDK) - a new group of medicines in therapy of advanced breast cancer].
    Sarosiek T
    Pol Merkur Lekarski; 2018 Jan; 44(259):5-9. PubMed ID: 29374415
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.
    Byrd JC; Smith S; Wagner-Johnston N; Sharman J; Chen AI; Advani R; Augustson B; Marlton P; Commerford SR; Okrah K; Liu L; Murray E; Penuel E; Ward AF; Flinn IW
    Oncotarget; 2019 Jun; 10(38):3827-3830. PubMed ID: 31217910
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Büyükkaramikli NC; de Groot S; Riemsma R; Fayter D; Armstrong N; Portegijs P; Duffy S; Kleijnen J; Al MJ
    Pharmacoeconomics; 2019 Feb; 37(2):141-153. PubMed ID: 30194622
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Cell cycle inhibitors in endocrine receptor positive breast cancer].
    Sablin MP; Ricci F; Loirat D; Jobard A; Basse C; Romano E; Le Tourneau C; Dieras V
    Bull Cancer; 2017 Feb; 104(2):114-122. PubMed ID: 28126188
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Correction: Glioblastoma and glioblastoma stem cells are dependent on functional MTH1.
    Pudelko L; Rouhi P; Sanjiv K; Gad H; Kalderén C; Höglund A; Squatrito M; Schuhmacher AJ; Edwards S; Hägerstrand D; Berglund UW; Helleday T; Bräutigam L
    Oncotarget; 2020 Feb; 11(8):827. PubMed ID: 32166004
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Correction: Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5.
    Al-Jameel W; Gou X; Forootan SS; Fayi MSA; Rudland PS; Forootan FS; Zhang J; Cornford PA; Hussain SA; Ke Y
    Oncotarget; 2020 Aug; 11(31):3025. PubMed ID: 32821347
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Correction:
    Alsubi TA; Attwa MW; Bakheit AH; Darwish HW; Abuelizz HA; Kadi AA
    RSC Adv; 2020 Jun; 10(40):23930. PubMed ID: 35532509
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Correction:
    Contis-Montes de Oca A; Rodarte-Valle E; Rosales-Hernández MC; Abarca-Rojano E; Rojas-Hernández S; Fragoso-Vázquez MJ; Mendieta-Wejebe JE; Correa-Basurto AM; Vázquez-Moctezuma I; Correa-Basurto J
    Oncotarget; 2019 Feb; 10(11):1225. PubMed ID: 30838095
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Correction: Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells.
    Novohradsky V; Zajac J; Vrana O; Kasparkova J; Brabec V
    Oncotarget; 2018 Oct; 9(85):35599. PubMed ID: 30473754
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Correction: A tissue factor-cascade-targeted strategy to tumor vasculature: a combination of EGFP-EGF1 conjugation nanoparticles with photodynamic therapy.
    Shi W; Yin Y; Wang Y; Zhang B; Tan P; Jiang T; Mei H; Deng J; Wang H; Guo T; Pang Z; Hu Y
    Oncotarget; 2018 Apr; 9(25):17979. PubMed ID: 29707163
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Correction: Inhibition of fibroblast secreted QSOX1 perturbs extracellular matrix in the tumor microenvironment and decreases tumor growth and metastasis in murine cancer models.
    Feldman T; Grossman-Haham I; Elkis Y; Vilela P; Moskovits N; Barshack I; Salame TM; Fass D; Ilani T
    Oncotarget; 2020 Oct; 11(40):3687. PubMed ID: 33088428
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Correction: Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance.
    Zhitomirsky B; Assaraf YG
    Oncotarget; 2022; 13():585-586. PubMed ID: 35391719
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Correction: CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models.
    Witkiewicz AK; Cox D; Knudsen ES
    Genes Cancer; 2021; 12():25-27. PubMed ID: 33884103
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Correction: Kupffer cells-dependent inflammation in the injured liver increases recruitment of mesenchymal stem cells in aging mice.
    Yang X; Liang L; Zong C; Lai F; Zhu P; Liu Y; Jiang J; Yang Y; Gao L; Ye F; Zhao Q; Li R; Han Z; Wei L
    Oncotarget; 2020 Oct; 11(42):3805-3806. PubMed ID: 33144922
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Correction to "Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP
    Sandham DA; Barker L; Brown L; Brown Z; Budd D; Charlton SJ; Chatterjee D; Cox B; Dubois G; Duggan N; Hall E; Hatto J; Leblanc C; Maas J; Manini J; Profit R; Riddy D; Ritchie C; Sohal B; Shaw D; Stringer R; Sykes DA; Thomas M; Turner KL; Watson SJ; West R; Willard E; Williams G; Willis J
    ACS Med Chem Lett; 2017 Sep; 8(9):987. PubMed ID: 28947949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.